Once you were I was we were
one. You
maybe instead
were
one of many
but we still were
one.
One donut, whole no hole.
Now. Now.
You’ve gone…
My grandmother made a dish similar to this which she called Chicken and Kasha. It’s a simple hearty winter stew, and buckwheat is a delicious and incredibly healthful food. Don’t let its name fool you – buckwheat is a seed, not a grain...
Max Szadek is the Founder and Executive Director of Divabetic®. Szadek, who toured with pop singers Luther Vandross and Lionel Richie, left that…
Novo Nordisk launched Cornerstones4Care™, a comprehensive, highly customizable online support program for people living with diabetes.
The program aims to be a one-stop source to learn about diabetes and innovative Novo Nordisk treatment options and delivery device systems. People can also receive recipes, look up food nutritional values, connect with others...
Wearing weighted vests turns a simple walk into a strength training workout...
The New York Times reported on the rapidly growing diabetes epidemic in the Middle East and North Africa and the financial burden of health care costs to the region’s governments.
Six countries in the region are among the top 10 globally with the highest prevalence of diabetes. They include the United Arab Emirates, showing the second-highest rate in the world — behind only the tiny Pacific island state of Nauru — followed by Bahrain, Egypt, Kuwait, Oman and Saudi Arabia...
The University of California, San Francisco (UCSF) and sanofi-aventis have formed two new research and development collaborations that join together leaders from academia and industry to more rapidly advance groundbreaking innovation from the lab to the patient. The first collaboration promotes innovative research in pharmacological science and in multiple therapeutic areas, such as oncology, aging, diabetes and inflammation...
Last week on “Good Morning America” actress and former talk show host, Ricki Lake, said juvenile diabetes was preventable. She’s…
Eli Lilly and Company and Boehringer Ingelheim announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim's two oral diabetes agents—linagliptin and BI10773—as well as Lilly's two basal insulin analogues—LY2605541 and LY2963016—as well as the option to co-develop and co-commercialize Lilly's anti-TGF-beta monoclonal antibody....
Biocon Ltd., India's largest biotechnology company, released preliminary data from a recently concluded clinical study conducted in India, on IN-105, its novel oral insulin candidate for the treatment of diabetes.
The study included 264 patients poorly controlled on metformin, who were randomly chosen receive either IN-105 or placebo...